User login
The Food and Drug Administration announced on Aug. 16 the approval of another new vaccine that protects against four strains of seasonal influenza in people aged 3 years and older.
The new vaccine, Flulaval Quadrivalent, is an intramuscular quadrivalent vaccine, named for its ability to protect against two A virus strains and two B virus strains of the influenza virus and is manufactured by GlaxoSmithKline. Until 2012, influenza vaccines protected against only one B virus strain, Dr. Leonard Friedland, vice president and director of scientific affairs and public health for GSK Vaccines North America, noted in a written statement.
"Trivalent vaccines do reduce influenza risk, even in years when a vaccine strain-mismatch occurs, though quadrivalent influenza vaccines are the important next step in broadening strain coverage," said Dr. Friedland.
GlaxoSmithKline will begin distributing the drug in time for the 2013-2014 flu season.
The Food and Drug Administration announced on Aug. 16 the approval of another new vaccine that protects against four strains of seasonal influenza in people aged 3 years and older.
The new vaccine, Flulaval Quadrivalent, is an intramuscular quadrivalent vaccine, named for its ability to protect against two A virus strains and two B virus strains of the influenza virus and is manufactured by GlaxoSmithKline. Until 2012, influenza vaccines protected against only one B virus strain, Dr. Leonard Friedland, vice president and director of scientific affairs and public health for GSK Vaccines North America, noted in a written statement.
"Trivalent vaccines do reduce influenza risk, even in years when a vaccine strain-mismatch occurs, though quadrivalent influenza vaccines are the important next step in broadening strain coverage," said Dr. Friedland.
GlaxoSmithKline will begin distributing the drug in time for the 2013-2014 flu season.
The Food and Drug Administration announced on Aug. 16 the approval of another new vaccine that protects against four strains of seasonal influenza in people aged 3 years and older.
The new vaccine, Flulaval Quadrivalent, is an intramuscular quadrivalent vaccine, named for its ability to protect against two A virus strains and two B virus strains of the influenza virus and is manufactured by GlaxoSmithKline. Until 2012, influenza vaccines protected against only one B virus strain, Dr. Leonard Friedland, vice president and director of scientific affairs and public health for GSK Vaccines North America, noted in a written statement.
"Trivalent vaccines do reduce influenza risk, even in years when a vaccine strain-mismatch occurs, though quadrivalent influenza vaccines are the important next step in broadening strain coverage," said Dr. Friedland.
GlaxoSmithKline will begin distributing the drug in time for the 2013-2014 flu season.
